Sermorelin Side Effects: What's Proven, What's Not, and When to Get Help

By the TRT Provider Guide Editorial Team · Last verified: October 2026 · Educational information, not medical advice. Editorial research; this page has not been clinically reviewed.

Last updated: October 26, 2026.

Affiliate disclosure: TRT Provider Guide may earn compensation through certain provider links. Commercial relationships do not change our editorial conclusions. Full disclosure.

The best-documented sermorelin side effect is a reaction where you inject it: pain, swelling or redness. In the historical pediatric trials behind Geref, that happened in about 1 in 6 patients. Headache, flushing, dizziness, trouble swallowing, hyperactivity, sleepiness and hives were each reported in fewer than 1 in 100. Those historical rates do not tell us how often the same effects occur in adults using today's compounded products.

But the side effects aren't the hard part of the safety question. The hard part is how little anyone knows about long-term adult use. Adult studies of GHRH(1-29), sermorelin or closely related analogs were small and short; the longest normal-aging studies we found lasted about six months. And no FDA-approved sermorelin product is currently marketed. Sermorelin dispensed today is generally compounded, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.

Keep reading if:

• you've been offered sermorelin and want the honest risk picture first
• you're already taking it and noticed something new
• you heard it was "pulled from the market" and want to know why
• you're weighing whether long-term use makes sense

What this page can't do:

• tell you whether a symptom was caused by sermorelin
• decide whether sermorelin is safe for you
• tell you to start, stop or change a prescription. That's a conversation with your prescriber.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

Sermorelin side effects at a glance

What we actually verified (October 2026)

Sources we checked directly:

• the FDA regulatory record for Geref
• archived historical Geref prescribing information, corroborated against current Mayo Clinic/Micromedex drug information
• current FDA compounding guidance
• the FDA label for tesamorelin (Egrifta), used only as related-drug context
• the DEA's current controlled-substance schedules
• the WADA 2026 Prohibited List
• published adult GHRH/sermorelin studies listed below

Confirmed:

• historical Geref side-effect rates and thyroid warning
• that FDA found Geref was not withdrawn for safety or effectiveness reasons
• that no FDA-approved sermorelin product is currently marketed
• that compounded drugs are not FDA-approved and are not premarket-reviewed by FDA for safety, effectiveness or quality
• that sermorelin is named on WADA's 2026 Prohibited List as a growth-hormone-releasing factor prohibited at all times

Could not establish:

• a dependable years-long side-effect rate for healthy adults using current compounded sermorelin
• a modern adult incidence rate for fluid retention, joint symptoms, vivid dreams, anxiety or similar commonly discussed symptoms
• that a particular compounded preparation has the same safety profile as historical Geref

What are the most common sermorelin side effects?

In the historical pediatric trials behind Geref, the most common treatment-related side effect was an injection-site reaction (pain, swelling or redness) in about 1 in 6 patients. Headache, flushing, trouble swallowing, dizziness, hyperactivity, sleepiness and hives were each reported in fewer than 1 in 100. Those figures are historical pediatric data, not modern adult incidence rates for compounded sermorelin.

First, a quick map of what sermorelin is, because it explains every side effect below.

Sermorelin is a lab-made copy of the first 29 building blocks of GHRH (growth hormone-releasing hormone). GHRH is the signal your brain sends to your pituitary gland, a pea-sized gland at the base of the brain, telling it to release growth hormone. Growth hormone then tells your liver to make IGF-1 (insulin-like growth factor 1). So the chain goes like this:

Sermorelin → pituitary → growth hormone → liver → IGF-1

Some side effects come from the shot itself. Others come from turning up that chain.

Injection-site reactions: the one most people get

This is the big one. The Geref label says local reactions (pain, swelling or redness) affected about 1 in 6 patients. Out of 350 people who got sermorelin in trials, 3 stopped because of them. Most people kept going.

Your prescriber or pharmacist should show you how to inject and where. The label advises rotating injection sites. If a reaction is spreading, worsening, unusually painful, draining, or otherwise concerning, contact your prescriber rather than assuming it is routine.

Headache, flushing, dizziness and sleepiness

Each of these showed up in fewer than 1 in 100 patients on daily treatment. That's lower than many sellers suggest. "Sleepiness" being on the list doesn't mean sermorelin improves sleep. That's a different claim, and the evidence for it is weak (more on that below).

Hives and trouble swallowing

Also under 1% each in the historical pediatric trials. Hives without breathing or swelling symptoms still deserve medical advice. Trouble breathing, or swelling of the face, lips, tongue or throat, can be an emergency. Call 911 in the U.S. or your local emergency number.

Side effects from the IV test version

Geref was also used as a one-time IV test of pituitary function. In that setting, historical prescribing information lists face flushing, injection-site pain, nausea, headache, vomiting, a strange taste, paleness and chest tightness. That's a different route and use, so those IV-test reactions should not be presented as incidence data for current compounded injections. New chest pain or tightness needs prompt medical evaluation.

Thyroid changes

This one surprises people. In the Geref trials, 6.5% of patients developed an underactive thyroid (hypothyroidism) during treatment. An untreated underactive thyroid can also blunt how well sermorelin works. That's why the label says to check thyroid levels before you start and during treatment.

---

How sure are we? The sermorelin side-effect evidence map

Not every "sermorelin side effect" you read about has the same proof behind it. Some come from historical sermorelin prescribing information, some from a related drug, some from small adult studies, and some only from user reports. Sorting them by evidence strength is the fastest way to see which risks are documented, which are plausible, and which are simply unknown.

Here's the rule we used to build this page: documented ≠ suspected ≠ reported ≠ unknown. Most pages blend all four together. We don't.

The tiers:

• A — Historical sermorelin evidence: Geref prescribing information and pediatric trial data
• B — Related-drug evidence: tesamorelin is a different GHRH analog, so its warnings can show a class concern but cannot supply a sermorelin incidence rate
• C — Small adult studies: useful for short-term signals, not rare or years-long harms
• D — Long-term questions from growth hormone and IGF-1 research: biologically relevant, but not proof that sermorelin causes a specific outcome
• E — Customer-experience signals: useful for knowing what people ask about, not for proving causation or frequency
• F — Product-quality risk from compounding: separate from the molecule's own effects

Our take: in the historical trials, sermorelin's documented treatment-related side effects were mostly mild and mostly at the injection site. What's missing is dependable long-term safety data in adults using it for wellness or normal aging. That gap doesn't mean sermorelin is dangerous. It means anyone selling you certainty, in either direction, is going past the evidence.

What about bloating, water retention, joint pain, tingling or vivid dreams?

These symptoms come up often in user discussions, but none of them were measured in sermorelin's trials. Swelling, joint pain and tingling fingers are possible because they're known effects of raising growth hormone. Vivid dreams and anxiety are user reports only. None has a known adult rate, so report them rather than assuming they're normal.

People search these because they're living them. Here's what we can and can't say.

Bloating, puffiness and water retention

Sermorelin's label doesn't list fluid retention. But the label for tesamorelin, the related FDA-approved drug, does. It describes swelling, joint pain and carpal tunnel symptoms, and says they're thought to come from boosting growth hormone. So puffy hands or ankles on sermorelin are plausible, not proven. Users who report it often take other drugs too, which makes the cause hard to pin down. Either way, tell your prescriber. It can be a sign your IGF-1 has climbed higher than it should.

Joint aches and tingling fingers

Same story. Numbness or tingling in the fingers can be carpal tunnel, a known growth-hormone effect. It's a reason to call, not a reason to wait it out.

Sleep changes and vivid dreams

Sellers often promise better sleep. But in two six-month studies of nightly GHRH(1-29), the same molecule as sermorelin, given to healthy older adults, sleep quality did not improve. Some users report trouble falling asleep or vivid dreams in the first weeks. Those are anecdotes. Don't treat better sleep as a reason to start, and don't treat bad sleep as something to push through without telling your prescriber.

Anxiety, jitteriness or "just feeling off"

These show up in forums, not in studies. They're real experiences, but no one has shown that sermorelin causes them or how often. If something feels wrong, that's enough reason to call.

---

When should a sermorelin side effect get medical attention?

Mild injection-site redness or soreness and brief flushing are documented historical effects, but an article cannot tell whether a symptom is harmless in your case. Contact your prescriber for symptoms that persist, worsen, spread, keep returning or interfere with normal activity. Trouble breathing, facial or throat swelling, fainting, or severe/new chest pain or tightness needs urgent or emergency evaluation.

You can also report suspected medication problems to the FDA's MedWatch program at 1-800-FDA-1088 or through the FDA MedWatch website. This includes problems with compounded medicines.

Should you stop sermorelin if you have side effects?

A general article can't safely tell you to stop a prescription, because the right move depends on the symptom, how severe it is, why you're taking sermorelin, your other medicines and your health history. Contact the clinician who prescribed it for individualized instructions. If the reaction may be serious, get urgent or emergency care first.

What the historical information can support:

• Don't change the dose on your own. Use a prescribed medicine only as directed by the clinician responsible for it.
• Dependence was not reported in the historical Geref clinical trials. The old prescribing information described abuse or dependence as very unlikely.
• Adult withdrawal or rebound effects have not been well studied. We did not find a published adult study designed to measure a sermorelin withdrawal syndrome or a predictable timeline after stopping.

Who needs an individualized medical review before sermorelin?

The historical Geref prescribing information listed hypersensitivity to sermorelin or its ingredients as the formal contraindication and advised medical supervision for other conditions. Modern compounded adult use is different from that old pediatric indication, so cancer history, pituitary disease, diabetes, thyroid disease, pregnancy, breastfeeding, fertility plans and drug-tested sport should be reviewed with the appropriate clinician rather than turned into a universal online checklist.

This matters because many online lists mix sermorelin's old label with warnings from tesamorelin or growth hormone and present them all as sermorelin facts.

If one of these situations applies to you, the right next step may be primary care, endocrinology, oncology, reproductive care or another specialist—not an online checkout.

Questions to bring to your prescriber

Use this list instead of trying to turn an article into an eligibility test:

1. What exactly are we treating? A diagnosed condition, a symptom, or a wellness goal?
2. What evidence supports sermorelin for that goal in people like me?
3. Is the product compounded, and which pharmacy will dispense it?
4. Which risks on this page are directly documented for sermorelin, and which are only class-based or uncertain?
5. What will you monitor, and why?
6. Which symptoms should make me contact you promptly or seek urgent care?
7. What would make you reconsider continuing treatment?

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

What are the long-term side effects of sermorelin?

No one knows for sure. The longest normal-aging studies we found using GHRH(1-29) or closely related analogs lasted about six months, and none followed people for years. Short-term studies can't show rare or slow-building problems. IGF-1 is biologically relevant because these drugs raise the GH/IGF-1 axis, but a normal lab value cannot prove years-long safety.

Feeling fine after three months is good news. It just doesn't answer the long-term question. Rare problems need large groups of people. Slow problems need years. Sermorelin in healthy adults has had neither.

Here is everything the safety picture rests on:

Why the IGF-1 question matters

Sermorelin works by raising growth hormone, which raises IGF-1. The label confirms IGF-1 goes up. That's the point of the drug, and also the reason for long-term caution.

The best-known study here followed 633 men aged 50 and older for 18 years. Men with IGF-1 above 100 ng/mL had about 1.8 times the risk of dying from cancer, even after accounting for age, weight, lifestyle and past cancer. But that was an observational study. It shows a link, not proof that IGF-1 caused anything. And a larger 2011 review found that both very low and very high IGF-1 were tied to higher death rates.

So the lesson isn't "lower is safer" or "higher is better." These observational IGF-1 studies are a reason not to turn a higher IGF-1 result into a goal by itself. They do not establish a sermorelin cancer threshold or prove that keeping IGF-1 inside a reference range makes long-term sermorelin use safe.

Can sermorelin damage your pituitary?

There's no published evidence that sermorelin causes lasting pituitary damage. It works through your pituitary rather than replacing growth hormone, so it needs a working pituitary to do anything. But long-term studies that could prove or rule out damage don't exist. The label also says people whose growth hormone problem comes from a brain lesion shouldn't use it, because they were never studied.

---

Does sermorelin cause cancer?

No human study has established that sermorelin causes cancer, and no years-long adult study can rule out a change in risk. Because sermorelin raises the GH/IGF-1 axis and observational studies have linked higher IGF-1 with cancer outcomes in some populations, cancer history belongs in an individualized specialist discussion. The honest sermorelin-specific answer is: long-term risk is unknown.

This is the question that keeps people up at night, so here it is straight.

• No study shows sermorelin causes cancer.
• No study is long enough to show it doesn't.
• The related drug tesamorelin is contraindicated with active malignancy; that warning is related-drug context, not proof that sermorelin has the same quantified risk.
• Animal studies on cancer risk were never done for sermorelin, according to its label.

If someone tells you sermorelin "prevents cancer" or "has zero cancer risk," they're overselling it. If someone tells you it "causes cancer," they're overselling that too.

---

Can sermorelin raise blood sugar?

Raised blood sugar was not listed as a treatment-related adverse event in historical Geref information, and small adult GHRH studies did not find fasting-glucose changes. But the related FDA-approved drug tesamorelin carries a glucose-intolerance warning. If you have diabetes or prediabetes, ask the clinician whether and how glucose should be monitored for your specific treatment.

Growth hormone works against insulin to some degree. That's why the tesamorelin label tells doctors to check glucose before treatment and periodically after. Sermorelin's short adult studies are reassuring here (no fasting glucose change in Corpas 1992 or Khorram 1997), but they were small and short.

New symptoms such as unusual thirst, much more frequent urination or unexplained glucose changes deserve medical review rather than being automatically blamed on sermorelin.

---

Was sermorelin taken off the market because it was unsafe?

No. The FDA formally found in 2013 that Geref, the FDA-approved sermorelin, was not withdrawn for safety or effectiveness reasons. Its maker discontinued it, and the FDA withdrew its approvals effective June 18, 2009. That finding covers the old Geref product only. It doesn't make today's compounded sermorelin FDA-approved.

Here's the timeline:

Two common claims online are both wrong:

• ❌ "Sermorelin was pulled because it was dangerous." The FDA says otherwise.
• ❌ "The FDA says sermorelin is safe." The FDA's 2013 finding was about why an old product left the market. It says nothing about modern compounded products or adult wellness use.

Geref was never approved for anti-aging, body composition or wellness in adults. Every one of those uses is off-label.

---

Is compounded sermorelin safe?

A compounded sermorelin prescription is not an FDA-approved finished drug. FDA does not verify a compounded drug's safety, effectiveness or quality before it is marketed. That does not mean every compounded product is unsafe; it means the approval evidence and manufacturing oversight are different, and product quality is a separate part of the risk decision.

Here's the part many sellers skip: no FDA-approved sermorelin product is currently marketed. If having a currently FDA-approved finished product is a requirement for you, sermorelin does not meet that requirement.

But here's why that admission isn't the end of the story. The safety question has two parts: the effects of sermorelin/GH signaling, and the quality of the compounded product you actually receive.

Molecule risk vs. product risk

FDA says poor compounding practices can lead to contamination or a drug containing too much or too little active ingredient, with potentially serious harm.

"Compounded" is not "generic"

A generic drug is FDA-approved through an abbreviated approval pathway and must meet applicable FDA requirements. A compounded drug is not FDA-approved. FDA also warns telehealth companies not to claim that compounded products are "generic," the same as an FDA-approved drug, or made by an "FDA-approved" or "FDA-licensed" pharmacy or outsourcing facility.

"Research peptides" are a different decision

A product sold online as "for research use only" is not the same thing as a patient-specific prescription dispensed through lawful medical and pharmacy channels. Do not treat a research-use product as a substitute for prescribed care.

Is sermorelin a controlled substance?

Sermorelin is not listed as a federally controlled substance in the DEA schedules we checked in October 2026. That is different from testosterone, which is Schedule III. Not being DEA-scheduled does not mean an unapproved drug can be marketed or used without the other laws that apply to prescribing, compounding and pharmacy practice.

For drug-tested sport, a separate rule applies: the WADA 2026 Prohibited List names sermorelin under S2.2.4, growth-hormone-releasing factors, a class prohibited at all times.

The numbers you'll see online vs. what the label actually says

Many sermorelin side-effect pages repeat statistics that don't match the FDA label, including made-up antibody rates, inflated flushing rates and wrong claims about why it left the market. Checking each claim against the original source is the only way to know what's real.

We checked the claims that show up most across sermorelin side-effect pages. Here's what we found.

If a page gets the easy, checkable facts wrong, be careful trusting it on the hard ones.

---

How can you reduce avoidable risk if sermorelin is being considered?

The safest useful step is not a DIY protocol. It is making sure the reason for treatment, the compounded product, the clinician responsible for it and the follow-up plan are clear before you proceed. Historical sermorelin information supports thyroid monitoring, while other monitoring decisions should be individualized rather than copied from a different drug's label.

The five-point safety checklist

1. Know what is being treated. Ask whether the goal is a diagnosed condition, a symptom or a wellness objective, and what evidence supports sermorelin for that goal.
2. Know the exact product. Current sermorelin is compounded rather than an FDA-approved finished drug. Ask which pharmacy or outsourcing facility will prepare it and what formulation will be dispensed.
3. Know the follow-up plan. Historical Geref information called for thyroid testing. Ask what other labs or clinical checks your prescriber believes are appropriate for your health history and why.
4. Make sure a real clinician reviews the full history. Cancer history, pituitary disease, diabetes, thyroid disease, pregnancy, fertility plans and other medicines can change the decision.
5. Know how to report a problem. You should know how to reach the prescribing team and when they want you to use urgent or emergency care instead.

What IGF-1 testing can and can't tell you

IGF-1 can show that the GH/IGF-1 axis is responding, but it cannot prove that sermorelin is safe for you or diagnose adult growth hormone deficiency by itself. Adult growth hormone deficiency is a specialist diagnosis that usually relies on clinical context and, when needed, validated stimulation testing rather than one IGF-1 value.

If you are taking or considering sermorelin because of fatigue, body-composition changes, lower drive or other nonspecific symptoms, do not assume growth hormone is the cause. Those symptoms have many possible explanations.

Not sure which care route fits the problem you're trying to solve? Use TRT Provider Guide's Find My TRT Path tool to map your situation to the right next step and the questions to ask before you pay.

Does sermorelin affect testosterone, fertility or TRT?

Sermorelin works on the growth-hormone system, not the testosterone-replacement pathway. It is not TRT, and it should not be described as a treatment for testosterone deficiency. Direct long-term fertility data are limited, so fertility plans belong in the prescriber conversation rather than being treated as proven safe or harmful.

• Testosterone: sermorelin does not contain testosterone or replace it. Claims that it reliably "boosts testosterone" are not established by the historical Geref label.
• Fertility: the historical label notes that animal fertility studies were not performed. That is a data gap, not proof of harm or proof of safety.
• With TRT: some clinics prescribe GH-axis peptides alongside testosterone, but the 2017 Sigalos paper involved a combination of sermorelin, GHRP-2 and GHRP-6 in men already receiving testosterone. It cannot isolate sermorelin's separate effect.

If your real question might be low testosterone

Fatigue, body-composition changes and lower drive can have many causes. If low testosterone is a concern, diagnosis should be based on compatible symptoms or signs plus consistently low testosterone confirmed with appropriate repeat early-morning testing—not a quiz, one symptom or one isolated number.

If you're unsure whether this is a sermorelin question, a testosterone-evaluation question or something that belongs with primary care or endocrinology, use Find My TRT Path for a non-diagnostic care-route guide.

Is sermorelin safer than HGH or TRT?

A blanket "safer" claim is not proven. Sermorelin, recombinant human growth hormone (somatropin) and testosterone act on different systems, have different approved uses, and do not have the kind of long-term head-to-head evidence needed to rank their overall safety. A different mechanism can explain different side-effect patterns, but it does not prove lower long-term risk.

A 2007 systematic review of growth hormone in healthy older adults found small body-composition changes and more adverse events, and concluded that growth hormone could not be recommended as an anti-aging therapy. Sermorelin works upstream by stimulating GH release rather than supplying GH directly, but that mechanistic difference is not proof that sermorelin is safer over years.

Two words to watch for: "natural" and "bioidentical." Sermorelin is a synthetic peptide. Working through an endogenous hormone pathway does not, by itself, establish safety.

Is sermorelin worth the uncertainty for you?

Every active treatment has side effects, so "does sermorelin have side effects?" isn't the useful question. The better question is whether the benefit for your actual goal is supported well enough to justify the known side effects, the product-quality risk, the monitoring, the cost and the long-term unknowns. Six questions will tell you.

Bring these to your prescriber before you start, or before you renew:

1. What exactly are we treating? A diagnosis, a symptom, or a general wellness goal?
2. What evidence shows sermorelin helps that, in people like me? Ask for the study, not a testimonial.
3. Which pharmacy makes my sermorelin? Is it licensed, and is it named on my label?
4. Which side effects are documented for sermorelin, and which are only class-based or uncertain?
5. What will we monitor, and why?
6. What findings or symptoms would make you reconsider the plan?

If the answers are vague, that tells you something. Save or print these six questions and bring them to the clinician responsible for the prescription.

---

Sermorelin side effects: frequently asked questions

Is sermorelin safe?

Historical Geref data suggest short-term treatment-related effects were mostly injection-site reactions, with several other listed effects under 1% each in pediatric trials. Long-term adult safety has not been established, and today's sermorelin is generally compounded rather than sold as an FDA-approved finished product.

What are the most common side effects of sermorelin?

In historical pediatric Geref trials, pain, swelling or redness at the injection site occurred in about 1 in 6 patients. Headache, flushing, dizziness, hyperactivity, sleepiness, hives and trouble swallowing were each reported in under 1%. Those are not modern adult incidence rates.

How long do sermorelin side effects last?

The label doesn't say. Injection-site reactions were mild enough that only 3 of 350 trial patients stopped. If a side effect hasn't settled or keeps coming back, call your prescriber rather than waiting.

Does sermorelin cause cancer?

No human study has established that sermorelin causes cancer, and no years-long adult study can rule out a change in risk. Because it raises the GH/IGF-1 axis, cancer history should be discussed with the relevant specialist before treatment.

Can sermorelin cause water retention or joint pain?

These aren't on sermorelin's label, but the related drug tesamorelin lists fluid retention, joint pain and carpal tunnel symptoms tied to raising growth hormone. Report swollen hands or feet, tingling fingers or new joint pain.

Can sermorelin raise blood sugar?

It was not a listed treatment-related effect in historical Geref information, and small adult GHRH studies found no fasting-glucose change. The related drug tesamorelin carries a glucose-intolerance warning, so people with diabetes or prediabetes should ask their clinician whether glucose monitoring is appropriate.

Can sermorelin cause insomnia, anxiety or vivid dreams?

Users report these, but they weren't measured in trials. Sleepiness, not insomnia, is on the label (under 1%). Tell your prescriber instead of changing the timing or dose yourself.

Does sermorelin cause hair loss?

Hair loss isn't on the label, and we found no study linking the two. If you notice it, tell your prescriber, since other causes, including other hormones you take, are common.

Does sermorelin cause weight gain?

Weight gain is not a listed historical Geref treatment-related effect. Some users report hunger or fluid-related changes, but a dependable modern adult sermorelin rate has not been established.

Is sermorelin FDA-approved?

No currently marketed sermorelin product is FDA-approved. Geref had FDA approvals in 1990 and 1997, the approvals were withdrawn in 2009, and FDA later determined the products were not withdrawn for reasons of safety or effectiveness. Today's compounded sermorelin is not FDA-approved.

Why was sermorelin taken off the market?

Its maker stopped selling Geref, and the FDA withdrew the approvals in 2009. The FDA later found the withdrawal was not for safety or effectiveness reasons. That finding doesn't apply to today's compounded products.

Is sermorelin a steroid or a controlled substance?

It's a peptide, not an anabolic steroid, and sermorelin is not listed as a federally controlled substance in the DEA schedules we checked in October 2026. Testosterone, by contrast, is Schedule III. Controlled-substance status is separate from the laws governing prescription drugs and compounding.

Are sermorelin tablets safer than injections?

Non-injected compounded forms avoid a needle, but that does not establish equivalent absorption, effectiveness or overall safety. Published human evidence for oral or troche sermorelin is limited; see sermorelin tablets vs. injections for the formulation question.

What happens when you stop taking sermorelin?

Historical Geref information said dependence was very unlikely and reported no dependence in clinical trials. Adult withdrawal or rebound effects have not been well studied, so plan medication changes with the prescribing clinician.

Can women take sermorelin?

The label data covers children of both sexes, and some adult studies included women. Women should discuss it with their own clinician, especially if pregnant or breastfeeding. TRT Provider Guide focuses on men's hormone care.

Will sermorelin make me fail a drug test?

For sport governed by the World Anti-Doping Code, sermorelin is named in section S2.2.4 of the 2026 Prohibited List and is prohibited at all times. Athletes should check the rules that apply to them, including any therapeutic-use-exemption process.

How do I report a sermorelin side effect?

Tell your prescriber and the pharmacy that filled it. You can also report it to the FDA's MedWatch program at 1-800-FDA-1088.

---

How we researched this page

We built this page to answer one question well: what are sermorelin's real risks? We read the primary regulatory sources, separated historical pediatric data from modern adult compounded use, and sorted every major claim by the strength of its evidence. This is editorial research, not a clinical trial or hands-on product test.

Who: the TRT Provider Guide Editorial Team. This page has not been reviewed by a clinician.

How:

• We reviewed FDA's Geref regulatory record and current FDA compounding guidance.
• We cross-checked historical treatment-related effects against archived Geref prescribing information and current Mayo Clinic/Micromedex drug information.
• We used the current FDA tesamorelin label only for clearly labeled related-drug context, not as a source of sermorelin incidence rates.
• We checked the DEA controlled-substance schedules and the WADA 2026 Prohibited List.
• We reviewed the published adult studies listed below.
• We used customer discussions only to identify questions and experience signals, never as proof of medical causation, safety or frequency.
• We follow How We Review TRT Providers, which separates verified facts, provider-stated facts, customer-experience signals and editorial conclusions.

Why: most sermorelin pages either blend direct evidence with guesses or turn a data gap into certainty. You deserve to know which is which.

Sources

1. FDA / Federal Register: Geref products were not withdrawn for reasons of safety or effectiveness
2. FDA: Compounding and the FDA — Questions and Answers
3. FDA: Understanding the Risks of Compounded Drugs
4. FDA: What telehealth companies should know when promoting compounded drugs
5. Mayo Clinic / Micromedex: Sermorelin (injection route)
6. FDA: Egrifta (tesamorelin) prescribing information
7. DEA Diversion Control Division: Controlled Substance Schedules
8. WADA: 2026 Prohibited List
9. Corpas E et al., 1992: GHRH-(1-29) twice daily in older men
10. Khorram O et al., 1997: modified GHRH-(1-29) analog in older adults
11. Merriam GR et al. Growth hormone-releasing hormone treatment in normal aging. J Anti-Aging Med. 2001;4(4).
12. Sigalos JT et al., 2017: combination GHRP/sermorelin treatment in hypogonadal men
13. Major JM et al., 2010: IGF-I and cancer mortality in older men
14. Burgers AMG et al., 2011: IGF-I and mortality meta-analysis
15. Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–115.

The bottom line

Historical sermorelin data show that treatment-related side effects were mostly mild and mostly at the injection site. The real unknown is years of modern adult use, because the evidence is too small and short to give a dependable long-term risk rate. Product quality, the reason for treatment and clinical supervision all matter. If a major medical condition or concerning symptom applies to you, your next step is the appropriate clinician rather than an online safety article.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

This page is educational information, not medical advice. It can't tell you whether a symptom was caused by sermorelin or whether you should start, stop or change treatment. Contact the clinician who prescribed it for guidance. If you have trouble breathing, swelling of your face or throat, chest pain, or you faint, call 911.

Related reading:

• Sermorelin vs. TRT
• Sermorelin tablets vs. injections
• Sermorelin cost
• Getting sermorelin online
• TRT side effects